Consensus statement: Evaluation of new and existing therapeutics for pediatric multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 1, 2012, Pages 116-127

  Chitnis, T ^a   Tenembaum, S ^b   Banwell, B ^c   Krupp, L ^d   Pohl, D ^e   Rostasy, K ^f   Yeh, E A ^g   Bykova, O ^h   Wassmer, E ⁱ   Tardieu, M ^j   Kornberg, A ^k   Ghezzi, A ^l  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Dr Juan P Garrahan   (Argentina)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g UNIVERSITY AT BUFFALO   (United States)

^h Moscow Regional Veterans Hospital   (Russian Federation)

ⁱ BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^k ROYAL CHILDREN'S HOSPITAL   (Australia)

^l Hospital of Gallarate   (Italy)

more..

Author keywords

disease modifying therapies; multiple sclerosis

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; RITUXIMAB; TERIFLUNOMIDE;

ADOLESCENT; AMENORRHEA; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHENIA; BLADDER CANCER; BLOOD CELL COUNT; CARDIOTOXICITY; CHILD; CHILD DEVELOPMENT; CHILDHOOD DISEASE; CLINICAL TRIAL (TOPIC); CONSENSUS; DEPRESSION; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FERTILITY; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; IMMUNE SYSTEM; INFECTION; INFERTILITY; INJECTION SITE PAIN; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LEUKEMIA; MENORRHAGIA; MULTIPLE SCLEROSIS; MYALGIA; PATIENT MONITORING; PHARMACODYNAMICS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SECOND CANCER; SIDE EFFECT; TREATMENT OUTCOME;

EID: 84855965204     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511430704     Document Type: Article

References (79)

1. Duquette P, Murray TJ, Pleines J, Ebers GC, Sadovnick D, Weldon P, et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J Pediatr. 1987 ; 111: 359-363 (Pubitemid 17157505)
2. Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. Early onset multiple sclerosis: a longitudinal study. Neurology. 2002 ; 59: 1006-1010
3. Ghezzi A, Deplano V, Faroni J, Grasso MG, Liguori M, Marrosu G, et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler. 1997 ; 3: 43-46 (Pubitemid 27234861)
4. Sindern E, Haas J, Stark E, Wurster U. Early onset MS under the age of 16: clinical and paraclinical features. Acta Neurol Scand. 1992 ; 86: 280-284
5. Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler. 2009 ; 15: 627-631
6. Pohl D, Waubant E, Banwell B, Chabas D, Chitnis T, Weinstock-Guttman B, et al. Treatment of pediatric multiple sclerosis and variants. Neurology. 2007 ; 68 (Suppl. 2). S54 - S65
7. Yeh EA, Chitnis T, Krupp L, Ness J, Chabas D, Kuntz N, et al. Pediatric multiple sclerosis. Nat Rev Neurol. 2009 ; 5: 621-631
8. Kuntz NL, Chabas D, Weinstock-Guttman B, Chitnis T, Yeh EA, Krupp L, et al. Treatment of multiple sclerosis in children and adolescents. Expert Opin Pharmacother. 2010 ; 11: 505-520
9. Ghezzi A, Banwell B, Boyko A, Amato MP, Anlar B, Blinkenberg M, et al. The management of multiple sclerosis in children: a European view. Mult Scler. 2010 ; 16: 1258-1267
10. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002 ; 58: 169-178 (Pubitemid 34086933)
11. Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007 ; 68 (Suppl. 2). S7 - S12
12. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009 ; 66: 54-59
13. Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Portaccio E, et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology. 2008 ; 70: 1891-1897 (Pubitemid 351684642)
14. MacAllister WS, Belman AL, Milazzo M, Weisbrot DM, Christodoulou C, Scherl WF, et al. Cognitive functioning in children and adolescents with multiple sclerosis. Neurology. 2005 ; 64: 1422-1425 (Pubitemid 40570512)
15. Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Moiola L, et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology. 2010 ; 75: 1134-1140
16. Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. Natural history of multiple sclerosis with childhood onset. N Eng J Med. 2007 ; 356: 2603-2613 (Pubitemid 46961005)
17. Simone IL, Carrara D, Tortorella C, Liguori M, Lepore V, Pellegrini F, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology. 2002 ; 59: 1922-1928 (Pubitemid 36076565)
18. Trojano M, Paolicelli D, Bellacosa A, Fuiani A, Cataldi S, Di Monte E. Atypical forms of multiple sclerosis or different phases of a same disease?. Neurol Sci. 2004 ; 25 (Suppl. 4). S323 - S325
19. Waubant E, Chabas D, Okuda DT, Glenn O, Mowry E, Henry RG, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. 2009 ; 66: 967-971
20. Yeh EA, Weinstock-Guttman B, Ramanathan M, Ramasamy DP, Willis L, Cox JL, et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain. 2009 ; 132: 3392-3400
21. Waubant E, Hietpas J, Stewart T, Dyme Z, Herbert J, Lacy J, et al. Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics. 2001 ; 32: 211-213 (Pubitemid 32895904)
22. Mikaeloff Y, Moreau T, Debouverie M, Pelletier J, Lebrun C, Gout O, et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr. 2001 ; 139: 443-446 (Pubitemid 32889524)
23. Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu G, Martinelli V, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler. 2005 ; 11: 420-424 (Pubitemid 40984236)
24. Ghezzi A, Amato MP, Capobianco M, et al. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. Neurol Sci. 2007. 28 (3). 127-32
25. Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, et al. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci. 2009 ; 30: 193-199
26. Pohl D, Rostasy K, Gartner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology. 2005 ; 64: 888-890 (Pubitemid 40316332)
27. Tenembaum SN, Segura MJ. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology. 2006 ; 67: 511-513 (Pubitemid 44214986)
28. Banwell B, Reder AT, Krupp L, Tenembaum S, Eraksoy M, Alexey B, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006 ; 66: 472-476 (Pubitemid 43739870)
29. Kornek B, Bernert G, Balassy C, Geldner J, Prayer D, Feucht M. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics. 2003 ; 34: 120-126 (Pubitemid 36994400)
30. Waldman AT, Gorman MP, Rensel MR, Austin TE, Hertz DP, Kuntz NL. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol. 2011 ; 26: 675-682
31. Ghezzi A, Banwell B, Boyko A, Amato MP, Anlar B, Blinkenberg M, et al. The management of multiple sclerosis in children: a European view. Mult Scler. 2010 ; 16: 1258-1267
32. Yeh EA, Waubant E, Krupp LB, Ness J, Chitnis T, Kuntz N, et al. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurology. 2011 ; 68: 437-444
33. Bykova OV, Kuzenkova LM, Maslova OI. The use of beta-interferon-1b in children and adolescents with multiple sclerosis. Zh Nevrol Psikhiatr Im S S Korsakova. 2006 ; 106: 29-33
34. Callen DJ, Shroff MM, Branson HM, Li DK, Lotze T, Stephens D, et al. Role of MRI in the differentiation of ADEM from MS in children. Neurology. 2009 ; 72: 968-973
35. Callen DJ, Shroff MM, Branson HM, Lotze T, Li DK, Stephens D, et al. MRI in the diagnosis of pediatric multiple sclerosis. Neurology. 2009 ; 72: 961-967
36. Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology. 2006 ; 67: 258-262 (Pubitemid 44305409)
37. Mikaeloff Y, Adamsbaum C, Husson B, Vallee L, Ponsot G, Confavreux C, et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain. 2004 ; 127: 1942-1947 (Pubitemid 39150253)
38. Cohen BA, Khan O, Jeffery DR, Bashir K, Rizvi SA, Fox EJ, et al. Identifying and treating patients with suboptimal responses. Neurology. 2004 ; 63 (Suppl. 6). S33 - S40
39. Freedman MS, Cohen B, Dhib-Jalbut S, Jeffery D, Reder AT, Sandberg-Wollheim M, et al. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Curr Med Res Opin. 2009 ; 25: 2459-2470
40. Rio J, Nos C, Tintore M, Borras C, Galan I, Comabella M, et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol. 2002 ; 52: 400-406
41. Ghezzi A, Pozzilli C, Grimaldi LM, Brescia Morra V, Bortolon F, Capra R, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology. 2010 ; 75: 912-917
42. Yeh EA, Waubant E, Krupp LB, Ness J, Chitnis T, Kuntz N, et al. Multiple sclerosis therapies in pediatric patients With refractory multiple sclerosis. Arch Neurol. 2011 ; 68: 437-444
43. Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010 ; 9: 740-750
44. Borriello G, Prosperini L, Luchetti A, Pozzilli C. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol. 2009 ; 13: 67-71
45. Huppke P, Stark W, Zurcher C, Huppke B, Bruck W, Gartner J. Natalizumab use in pediatric multiple sclerosis. Arch Neurol. 2008 ; 65: 1655-1658
46. Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology. 2009 ; 72: 2076-2082
47. Chabas D, Castillo-Trivino T, Mowry EM, Strober JB, Glenn OA, Waubant E. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?. Neurology. 2008 ; 71: 1090-1093
48. Chabas D, Ness J, Belman A, Yeh EA, Kuntz N, Gorman MP, et al. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology. 2010 ; 74: 399-405
49. McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol. 2009 ; 183: 4067-4076
50. Chitnis T, Bar-Or A Pediatric Multiple Sclerosis. Chabas D Waubant E, ed. Cambridge University Press ; 2011 :
51. Banwell B, Bar-Or A, Giovannoni G, Dale RC, Tardieu M. Therapies for multiple sclerosis: considerations in the pediatric patient. Nature Rev Neurol. 2011 ; 7: 109-122
52. Guidance for Industry: General Considerations for Pediatric Pharmacokinetic STudies for Drugs and Biological Products. Washington, DC: US Department of Health and Human Services FaDACfDEaRC, Center for Biologics Evaluation and Research (CBER) ; 1998:
53. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res. 2002 ; 51: 236-243 (Pubitemid 34101340)
54. Lambert GH, Schoeller DA, Kotake AN, Flores C, Hay D. The effect of age, gender, and sexual maturation on the caffeine breath test. Dev Pharmacol Ther. 1986 ; 9: 375-388 (Pubitemid 17213887)
55. Arant BS. Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr. 1978 ; 92: 705-712
56. Taub DD, Longo DL. Insights into thymic aging and regeneration. Immunological reviews. 2005 ; 205: 72-93 (Pubitemid 40780178)
57. Weksler ME. Changes in the B-cell repertoire with age. Vaccine. 2000 ; 18: 1624-1628 (Pubitemid 30109519)
58. Vallejo AN. Age-dependent alterations of the T cell repertoire and functional diversity of T cells of the aged. Immunol Res. 2006 ; 36: 221-228 (Pubitemid 46398598)
59. Goronzy JJ, Lee WW, Weyand CM. Aging and T-cell diversity. Exp Gerontol. 2007 ; 42: 400-406 (Pubitemid 46561179)
60. Gorczynski RM, Kennedy M, MacRae S. Altered lymphocyte recognition repertoire during ageing. III. Changes in MHC restriction patterns in parental T lymphocytes and diminution in T suppressor function. Immunology. 1984 ; 52: 611-620 (Pubitemid 14094489)
61. Cossarizza A, Ortolani C, Paganelli R, Barbieri D, Monti D, Sansoni P, et al. CD45 isoforms expression on CD4+ and CD8+ T cells throughout life, from newborns to centenarians: implications for T cell memory. Mech Ageing Dev. 1996 ; 86: 173-195 (Pubitemid 26134554)
62. Faria AM, de Moraes SM, de Freitas LH, Speziali E, Soares TF, Figueiredo-Neves SP, et al. Variation rhythms of lymphocyte subsets during healthy aging. Neuroimmunomodulation. 2008 ; 15: 365-379
63. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Eng J Med. 2006 ; 354: 899-910
64. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Eng J Med. 2006 ; 354: 911-923
65. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010 ; 68: 295-303
66. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Path. 2009 ; 5: e1000363
67. Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol. 2003 ; 71: 115-123 (Pubitemid 37121921)
68. Ellis R, Boggild M. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?. Mult Scler. 2009 ; 15: 505-508
69. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010 ; 74: 1463-1470
70. Kornek B, Bernert G, Rostasy K, Mlczoch E, Feucht M, Prayer D, et al. Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis. Neuropediatrics. 2011 ; 42: 7-12
71. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Eng J Med. 1983 ; 308: 173-180 (Pubitemid 13171135)
72. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993 ; 43: 910-918 (Pubitemid 23150561)
73. Baca V, Lavalle C, Garcia R, Catalan T, Sauceda JM, Sanchez G, et al. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol. 1999 ; 26: 432-439 (Pubitemid 29066751)
74. Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011 ; 127: 303-312
75. Adams A, MacDermott EJ, Lehman TJ. Pharmacotherapy of lupus nephritis in children: a recommended treatment approach. Drugs. 2006 ; 66: 1191-1207 (Pubitemid 44050435)
76. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Eng J Med. 2008 ; 358: 676-688 (Pubitemid 351240747)
77. Tzaribachev N, Koetter I, Kuemmerle-Deschner JB, Schedel J. Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J. 2009 ; 2: 6609
78. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009 ; 10: 816-824
79. Rosen H, Alfonso C, Surh CD, McHeyzer-Williams MG. Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist. Proc Natl Acad Sci USA. 2003 ; 100: 10,907-10,912